Back to Search
PAUL HAMLIN, MD
MD
Medical Oncology Physician
NPI: 1376514315IndividualAccepts Medicare
Specialties, Licenses & Credentials
Medical Oncology PhysicianPrimary
Internal Medicine — Medical Oncology
Code: 207RX0202X
211763(NY)
CMS Specialties
PrimaryMEDICAL ONCOLOGY
Education
STATE UNIVERSITY OF NY UPSTATE MEDICAL UNIVERSITY
Class of 1997
Research & Publications (20)
Primary mediastinal large B-cell lymphoma: optimal therapy and prognostic factor analysis in 141 consecutive patients treated at Memorial Sloan Kettering from 1980 to 1999.
PMID 16115124·Br J Haematol·2005
8-other
Age-adjusted International Prognostic Index predicts autologous stem cell transplantation outcome for patients with relapsed or primary refractory diffuse large B-cell lymphoma.
PMID 12676776·Blood·2003
3-trial
Phase II-I-II study of two different doses and schedules of pralatrexate, a high-affinity substrate for the reduced folate carrier, in patients with relapsed or refractory lymphoma reveals marked activity in T-cell malignancies.
PMID 19652067·J Clin Oncol·2009
3-trial
Phase 2 study of weekly bortezomib in mantle cell and follicular lymphoma.
PMID 19624539·Br J Haematol·2009
3-trial
A population pharmacokinetic and pharmacodynamic evaluation of pralatrexate in patients with relapsed or refractory non-Hodgkin's or Hodgkin's lymphoma.
PMID 19474785·Clin Pharmacol Ther·2009
8-other
Placebo-controlled phase III trial of patient-specific immunotherapy with mitumprotimut-T and granulocyte-macrophage colony-stimulating factor after rituximab in patients with follicular lymphoma.
PMID 19414675·J Clin Oncol·2009
3-trial
Patients with chemotherapy-refractory mantle cell lymphoma experience high response rates and identical progression-free survivals compared with patients with relapsed disease following treatment with single agent bortezomib: results of a multicentre Phase 2 clinical trial.
PMID 19220284·Br J Haematol·2009
3-trial
The role of FDG-PET imaging and involved field radiotherapy in relapsed or refractory diffuse large B-cell lymphoma.
PMID 19139730·Bone Marrow Transplant·2009
8-other
The majority of transformed lymphomas have high standardized uptake values (SUVs) on positron emission tomography (PET) scanning similar to diffuse large B-cell lymphoma (DLBCL).
PMID 19139176·Ann Oncol·2009
8-other
Visceral Leishmaniasis presenting with intestinal failure: a case report and literature review.
PMID 19011572·Eur J Gastroenterol Hepatol·2009
5-case
Do six or eight cycles work better with CHOP-14 and rituximab?
PMID 18706266·Curr Oncol Rep·2008
3-trial
A multicentre phase II clinical experience with the novel aza-epothilone Ixabepilone (BMS247550) in patients with relapsed or refractory indolent non-Hodgkin lymphoma and mantle cell lymphoma.
PMID 18691173·Br J Haematol·2008
3-trial
Infectious disease associations in advanced stage, indolent lymphoma (follicular and nonfollicular): developing a lymphoma prevention strategy.
PMID 17965114·Ann Oncol·2008
8-other
Abnormal T cell differentiation persists in patients with rheumatoid arthritis in clinical remission and predicts relapse.
PMID 17644540·Ann Rheum Dis·2008
4-observational
Maintaining the dose intensity of ICE chemotherapy with a thrombopoietic agent, PEG-rHuMGDF, may confer a survival advantage in relapsed and refractory aggressive non-Hodgkin lymphoma.
PMID 17872903·Ann Oncol·2007
3-trial
Mycophenolate mofetil therapy for refractory inflammatory bowel disease.
PMID 17924566·Inflamm Bowel Dis·2007
8-other
Pralatrexate, a novel class of antifol with high affinity for the reduced folate carrier-type 1, produces marked complete and durable remissions in a diversity of chemotherapy refractory cases of T-cell lymphoma.
PMID 17910632·Br J Haematol·2007
3-trial
Identifying vulnerable older adults with cancer: integrating geriatric assessment into oncology practice.
PMID 17697101·J Am Geriatr Soc·2007
8-other
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 1275 YORK AVE
NEW YORK, NY 10021 - Phone
- (212) 639-2000
Quick Facts
- NPI
- 1376514315
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Accepted
- Specialties
- 1
- Locations
- 1
- Years in Practice
- 29
- Publications
- 20
Are you this provider?
Claim Your Profile